Design Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	16.86	22.56	21.2	26.5	298.57
Short-Term Investments	202.99	222.91	260.6	303.89	85.5
Cash & Short-Term Investments	219.85	245.48	281.8	330.39	384.06
Cash Growth	-10.44%	-12.89%	-14.71%	-13.98%	964.15%
Other Current Assets	3.94	2.56	2.79	4.73	1.37
Total Current Assets	223.78	248.04	284.58	335.12	385.44
Net Property, Plant & Equipment	2.42	3.63	4.63	5.56	5.12
Other Long-Term Assets	-	0.43	0.43	0.46	-
Total Assets	226.2	252.09	289.64	341.14	390.56
Accounts Payable	2.31	2.19	1.94	3.03	1.62
Accrued Expenses	10.74	6.28	7.68	7.75	3.66
Total Current Liabilities	13.06	8.46	9.62	10.78	5.28
Long-Term Leases	0.65	1.53	2.33	3.05	3.14
Total Long-Term Liabilities	0.65	1.53	2.33	3.05	3.14
Total Liabilities	13.7	10	11.96	13.83	8.43
Common Stock	0.01	0.01	0	0.01	0.01
Additional Paid-in Capital	509.1	468.83	455.25	441.42	429.82
Accumulated Other Comprehensive Income	0.4	0.48	0.06	-3.36	-0.24
Retained Earnings	-297.01	-227.21	-177.63	-110.76	-47.46
Total Common Shareholders' Equity	212.5	242.1	277.69	327.31	382.13
Shareholders' Equity	212.5	242.1	277.69	327.31	382.13
Total Liabilities & Equity	226.2	252.09	289.64	341.14	390.56
Total Debt	0.65	1.53	2.33	3.05	3.14
Net Cash (Debt)	219.2	243.94	279.46	327.34	380.92
Net Cash Growth	-10.14%	-12.71%	-14.63%	-14.07%	955.44%
Net Cash Per Share	3.82	4.31	4.99	5.88	8.29
Book Value	212.5	242.1	277.69	327.31	382.13
Book Value Per Share	3.71	4.28	4.96	5.88	8.32
Tangible Book Value	212.5	242.1	277.69	327.31	382.13
Tangible Book Value Per Share	3.71	4.28	4.96	5.88	8.32

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q